US FDA Clearance For Enzon Trial

30 January 1995

Enzon has received clearance from the US Food and Drug Administration to begin clinical trials of its hemoglobin-based oxygen carrier, PEG-hemoglobin, for adjunct treatment of cancer patients undergoing radiation therapy and transfusion during trauma and general surgery.

Abraham Abuchowski, chief scientific officer at the company, said that recent data confirms earlier animal studies that had shown that PEG-hemoglobin can dramatically improve the effectiveness of radiation therapy against large tumor masses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight